Drug profile · INN
odevixibat
BYLVAY
odevixibat (BYLVAY) is a ileal bile acid transporter inhibitor. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
Drug details — odevixibat
- US status
- approved
- Class
- Alimentary tract and metabolism (A05)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
odevixibat (BYLVAY) is a ileal bile acid transporter inhibitor. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Ileal bile acid transporter inhibitor
Primary target: Ileal sodium/bile acid cotransporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is odevixibat?
odevixibat (BYLVAY) is a ileal bile acid transporter inhibitor. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for odevixibat?
BYLVAY is a marketed brand name for odevixibat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of odevixibat?
odevixibat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.